SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Emerging drugs for focal epilepsy.

Mula, M (2018) Emerging drugs for focal epilepsy. Expert Opin Emerg Drugs, 23 (3). pp. 243-249. ISSN 1744-7623 https://doi.org/10.1080/14728214.2018.1527903
SGUL Authors: Mula, Marco

[img] Microsoft Word (.docx) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (49kB)

Abstract

INTRODUCTION: Epilepsy is one of the most serious neurological conditions, affecting almost 50 million people around the world. Despite more than 20 antiepileptic drugs (AEDs) available, seizures are still uncontrolled in one third of patients. Areas covered: The present paper reviews current compounds in preclinical and clinical development for the treatment of focal epilepsies and new potential molecular targets recently identified. Expert opinion: 1OP-2198, Cannabidavirin, Everolimus, FV-082, Ganaxolone, Minocycline, NAX 810-2, Padsevonil and Selurampanel seem to be particularly promising in focal epilepsy. Some of them, Everolimus and Ganaxolone, are already completing Phase III development while others are still at a preclinical stage. Everolimus represents the first example of precision-medicine in epilepsy and the first generation of disease-modifying agents but data on long-term safety are needed. Among AEDs in Phase II development, Cannabidavirin, Padsevonil and Selurampanel may represent a promising fourth generation of compounds for focal epilepsies if they successfully proceed to subsequent stages. Data on general tolerability, effects of cognition and behavior as well as the potential for interactions in polytherapy will be key element for the success or decline of these drugs.

Item Type: Article
Additional Information: This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Emerging Drugs on 25/9/18, available online: http://www.tandfonline.com/10.1080/14728214.2018.1527903
Keywords: 1OP-2198, Cannabidavirin, Epilepsy, FV-082, Ganaxolone, NAX 810-2, Padsevonil, Selurampanel, antiepileptic drugs, everolimus, minocycline, 1115 Pharmacology And Pharmaceutical Sciences, Pharmacology & Pharmacy
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Journal or Publication Title: Expert Opin Emerg Drugs
ISSN: 1744-7623
Language: eng
Dates:
DateEvent
27 September 2018Published
25 September 2018Published Online
20 September 2018Accepted
Publisher License: Publisher's own licence
PubMed ID: 30251907
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/110415
Publisher's version: https://doi.org/10.1080/14728214.2018.1527903

Statistics

Item downloaded times since 23 Nov 2018.

Actions (login required)

Edit Item Edit Item